ResMed Inc. (RMD)
NYSE · Healthcare · Medical Instruments & Supplies
$222.86+1.81%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $31.3B
- P/E (trailing)
- 21.4
- Forward P/E
- 16.8
- Dividend yield
- 1.2%
- 52-week range
- $180.27 – $284.87
- 52-week change
- −22.73%
- EPS (trailing)
- $10.43
- Analyst rating
- 2.3 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Jun 2026
- Revenue
- $5.7B (+9.85%)
- Net income
- $1.5B
- Operating margin
- 33.4%
- Diluted EPS
- $10.43
- Free cash flow
- $1.6B
From the company’s annual report on SEC EDGAR.
About ResMed Inc.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.
Headquarters: San Diego, United States · 11,370 employees · resmed.com